BIOVENTIX PLC

AGM Information • Dec 4, 2025

National Storage Mechanism | Additional information

RNS Number : 3397K

BioVentix PLC

04 December 2025

Bioventix PLC

("Bioventix" or the "Company")

Result of AGM

Bioventix PLC (AIM: BVXP) a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that at its Annual General Meeting held today, all resolutions put to shareholders were duly passed.

For further information please contact:

Bioventix plc		Tel: 01252 728 001
Peter Harrison	Chief Executive Officer
Cavendish Capital Markets Limited		Tel: 020 7220 0500
Geoff Nash/Elysia Bough	Corporate Finance
Nigel Birks/Harriet Ward	ECM

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBUBDDIUGDGUS